165115-70-8

Basic information

• Product Name: 4-(2,4-difluorophenyl)-pent-4-enoic acid
• Synonyms: 4-(2,4-difluorophenyl)-pent-4-enoic acid
• CAS NO: 165115-70-8
• Molecular Weight: 212.196
• Mol File: 165115-70-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 306.2±32.0 °C(Predicted)
• Density: 1.238±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-(2,4-difluorophenyl)-pent-4-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,4-difluorophenyl)-pent-4-enoic acid(165115-70-8)
• EPA Substance Registry System: 4-(2,4-difluorophenyl)-pent-4-enoic acid(165115-70-8)

Safety Data

• Hazardous Substances Data: 165115-70-8(Hazardous Substances Data)

Usage

General Description

4-(2,4-difluorophenyl)-pent-4-enoic acid is a chemical compound with the molecular formula C11H10F2O2. It is a pentenoic acid derivative with a specific substitution pattern of difluorophenyl at the 4-position. 4-(2,4-difluorophenyl)-pent-4-enoic acid may have applications in organic synthesis, pharmaceuticals, or materials science. With its unique structure and properties, 4-(2,4-difluorophenyl)-pent-4-enoic acid has the potential to be utilized in various chemical and biological processes, making it an interesting target for further research and development.

Upstream product

• 110931-77-6 4-(2,4-difluorophenyl)-4-oxobutanoic acid 
• 19493-09-5 Methylenetriphenylphosphorane 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 108-30-5 succinic acid anhydride 
• 372-18-9 1,3-Difluorobenzene 
• 2065-66-9 methyl-triphenylphosphonium iodide 
• 141113-36-2 2-(2,4-difluorophenyl)allyl alcohol 

Downstream Products

• 182009-37-6 4-(2,4-Difluoro-phenyl)-pent-4-enoyl chloride 
• 170985-86-1 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-1H-1,2,4-triazol-5(4H)-one 
• 171228-49-2 posaconazote 
• 149809-43-8 (2R-cis)-2-(2,4-difluorophenyl)-4-[[(4-methylphenyl)sulfonyloxy]methyl]-2-[(1H-1,2,4-triazol-1-yl)methyl]tetrahydrofuran 
• 182210-71-5 ((3R,5R)-5-(2,4-difluorophenyl)-5-(iodomethyl)tetrahydrofuran-3-yl)methanol 
• 160709-02-4 ((3R,5R)-5-((1H-1,2,4-triazole-1-yl) methyl)-5-(2,4-difluorophenyl) tetrahydrofuran-3-yl)methanol 
• 165115-74-2 (R)-4-benzyl-3-(4-(2,4-difluorophenyl)pent-4-enoyl)oxazolidin-2-one 
• 182009-45-6 (R)-4-benzyl-3-((S)-4-(2,4-difluorophenyl)-2-(hydroxymethyl)pent-4-enoyl)oxazolidin-2-one 

Relevant articles and documents

Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors

Inhibition of the hedgehog (Hh) signaling pathway has been validated as a therapeutic strategy to treat basal cell carcinoma and holds potential for several other forms of human cancer. Itraconazole and posaconazole are clinically useful triazole anti-fungals that are being repurposed as anti-cancer agents based on their ability to inhibit the Hh pathway. We have previously demonstrated that removal of the triazole from itraconazole does not affect its ability to inhibit the Hh pathway while abolishing its primary side effect, potent inhibition of Cyp3A4. To develop structure-activity relationships for the related posaconazole scaffold, we synthesized and evaluated a series of des-triazole analogues designed through both ligand- and structure-based methods. These compounds demonstrated improved anti-Hh properties compared to posaconazole and enhanced stability without inhibiting Cyp3A4. In addition, we utilized a series of molecular dynamics and binding energy studies to probe specific interactions between the compounds and their proposed binding site on Smoothened. These studies strongly suggest that the tetrahydrofuran region of the scaffold projects out of the binding site and that π-π interactions between the compound and Smoothened play a key role in stabilizing the bound analogues.

AZOLE ANALOGUES AND METHODS OF USE THEREOF

Disclosed herein are analogues of itraconazole that are both angiogenesis and hedgehog signaling pathway inhibitors, formulations thereof, including lipsome formulations thereof. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE

The present invention relates to process for the preparation of ((3S,5R)-5-((lH-l,2,4- triazol- 1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl-4-methylbenzene sulfonate compound of formula- 1 through novel intermediates. Further the said compound of formula- 1 is useful as a key intermediate for the preparation of Posaconazole.